Agios Pharmaceuticals (AGIO)

$AGIO Dog shit

$AGIO 8 years later and 50% lower …. Why ? Senior execs, that are clueless Each one worse than the other !

$AGIO these pathetic senior execs, last calculation, have 20 days to submit their flawed dream of SCD drug . Their exact words were ..” we will submit in the 1st quarter of 2026 “ with the FDA for SCD !!! Now , everyone knows here, THE LIE LIKE TRUMP !

$AGIO @NoelRichards_ ….find another biotech, this ticker is ran by misfits , no scientist left here, just selling insiders and laid off employees of firms that knew they were incompetent. Goff, jones, Fouse, Guehens , Milanova , right down the line 8 years under Fouse , $48 when she arrived …today , lucky to be at $28 , thru her fcuk ups A repeat of her existence ay Bunge (BG) Goff , arrived at $29 …hasn’t done crap for shareholders, since 2022, but sells shares every quarter . A company of losers , on the welfare train of public money

$AGIO biotech with trader interest, if buyers reclaim the range this could trend better

$AGIO lol….another stooge gets beaten by Goff @Gurujoe Hardly a Guru of agios….fools like you rush in to cuddle with biotech’s biggest misfits ..Fouse , Goff , Milanova , Jones , Gehrens …Chris Snowden left …but gave them the pipeline to cash, ty are pissing away with no value created at all

$AGIO Nice puff piece ..but management are imbeciles …always hyping and never deliver

$AGIO – Investor presentation call today: Management was extremely bullish on the strength of their approved mitapivat franchise (PK deficiency + thalassemia) and notably constructive about advancing the drug into sickle cell disease. Tone was confident. It appears the final FDA minutes from the pre-sNDA meeting could arrive within ~30 days — a major catalyst. If FDA supports a BLA submission, the addressable market for mitapivat could more than triple to >$3B peak revenue potential. Importantly, this upside excludes ~$1.2B in cash and does not factor in broader pipeline optionality. Also worth emphasizing: this is an oral therapy in a lifelong disease setting. Current base: • FY25 revenue ~$54M (Q4 ~$20M early launch ramp) • >$1B peak potential already guided in approved indications • Strong balance sheet removes financing risk SCD Phase 3 showed significant hemoglobin improvement and anti-hemolytic activity, though it missed the VOC primary endpoint resulting in a > 50% stock devaluation. The investment debate is now regulatory interpretation, not biology. If FDA allows submission → probability reset event + material TAM expansion. If additional study required → timeline risk, but solvency and franchise durability remain intact. Multiple 2026 pipeline readouts (incl. next-gen PK activators) add optionality. Framing: This is transitioning from a clinical binary to a regulatory probability setup layered on a commercial rare-disease platform. ⚠️ Not investment advice. Personal opinion only. Biotech investing carries substantial risk, including loss of capital. Conduct your own due diligence. Good luck longs!

$BATL $INDO $USEG $TMDE $AGIO Straight of Hormuz officially closed 🚀🚀🚀

$KYMR a true fcuking joke ..almost like a Trump Org !!! Smoke and mirrors and only 1.6B … Hell , the misfits down the street in Cambridge, Ma. At $AGIO , have 1.3B , with drug approvals , but they are misfits and so, $29 ..hahaha and this pos is at $80+ And AGIO, filed for a mixed shelf offering with revenue of 19M a quarter…so, who is blowing who, in the back room of KYMR ??? At AGIO..they just LIE !